| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,010,000 |
| Market
Cap: |
172.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $4.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 935 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
84,560 |
206,385 |
272,181 |
454,395 |
| Total Sell Value |
$393,343 |
$830,960 |
$965,155 |
$2,986,647 |
| Total People Sold |
6 |
6 |
7 |
9 |
| Total Sell Transactions |
7 |
20 |
25 |
42 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Perry Andrew |
Chief Commercial Officer |
• – – |
2023-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
56,300 |
|
- |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2023-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
160,000 |
436,282 |
|
- |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2023-03-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,886 |
|
-28% |
|
| Umstead John V. |
Chief Financial Officer |
• – – |
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
58,886 |
|
- |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2023-01-05 |
4 |
S |
$5.41 |
$3,942 |
D/D |
(729) |
36,439 |
|
47% |
|
| Hanson James S. |
General Counsel |
• – – |
2023-01-05 |
4 |
S |
$5.41 |
$3,942 |
D/D |
(729) |
41,087 |
|
47% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2023-01-05 |
4 |
S |
$5.41 |
$3,942 |
D/D |
(729) |
102,739 |
|
47% |
|
| Moses Jennifer K. |
CFO |
• – – |
2023-01-05 |
4 |
S |
$5.41 |
$3,942 |
D/D |
(729) |
57,820 |
|
47% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2023-01-04 |
4 |
S |
$5.58 |
$9,138 |
D/D |
(1,639) |
37,168 |
|
46% |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2023-01-04 |
4 |
S |
$5.58 |
$4,572 |
D/D |
(820) |
21,300 |
|
46% |
|
| Hanson James S. |
General Counsel |
• – – |
2023-01-04 |
4 |
S |
$5.58 |
$9,138 |
D/D |
(1,639) |
41,816 |
|
46% |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2023-01-04 |
4 |
S |
$5.58 |
$9,138 |
D/D |
(1,639) |
103,468 |
|
46% |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2023-01-04 |
4 |
S |
$5.58 |
$31,262 |
D/D |
(5,607) |
276,282 |
|
46% |
|
| Moses Jennifer K. |
CFO |
• – – |
2023-01-04 |
4 |
S |
$5.58 |
$9,138 |
D/D |
(1,639) |
58,549 |
|
46% |
|
| Murdock Terry L |
Chief Operating Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
17,900 |
38,807 |
|
- |
|
| Avagliano Mark |
Chief Business Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
20,600 |
42,155 |
|
- |
|
| Perry Andrew |
Chief Commercial Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,100 |
22,120 |
|
- |
|
| Hanson James S. |
General Counsel |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
17,900 |
43,455 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
17,900 |
105,107 |
|
- |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2023-01-03 |
4 |
S |
$5.85 |
$187,452 |
D/D |
(32,019) |
281,889 |
|
53% |
|
| Bailey John E. (jack) Jr. |
President and CEO |
• • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
80,700 |
313,908 |
|
- |
|
| Moses Jennifer K. |
CFO |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
22,300 |
60,188 |
|
- |
|
| Malik Rajesh |
Chief Medical Officer |
• – – |
2022-12-15 |
4 |
OE |
$0.30 |
$4,200 |
D/D |
14,000 |
87,207 |
|
- |
|
| Velleca Mark A. |
|
– • – |
2022-10-18 |
4 |
AS |
$11.70 |
$175,490 |
D/D |
(15,000) |
116,000 |
|
-68% |
|
| Velleca Mark A. |
|
– • – |
2022-10-18 |
4 |
OE |
$0.39 |
$5,850 |
D/D |
15,000 |
131,000 |
|
- |
|
334 Records found
|
|
Page 3 of 14 |
|
|
0.15 (3.21%) 
